Thomas Xu is a graduate student at the Ragon Institute of MGH, MIT, and Harvard since September 2019, focusing on research related to immunology. Previously served as a research technician at Lefkowitz Lab from June 2016 to June 2017, contributing to GPCR research. Thomas Xu is pursuing a Doctor of Medicine (MD) degree at both Harvard Medical School and the Massachusetts Institute of Technology, along with a Doctor of Philosophy (PhD) in Immunology at Harvard Medical School, anticipated to be completed by 2026. Educational background includes a Bachelor of Science in Chemistry from Duke University, completed in 2016, and high school education at The Bronx High School of Science.
This person is not in the org chart
This person is not in any teams
Ragon Institute of Mass General, MIT, and Harvard
1 followers
The Ragon Institute was established in 2009 with a dual mission: to contribute to the accelerated discovery of an HIV/AIDS vaccine and subsequently establish itself as a world leader in the collaborative study of immunology. Founded with a commitment of $100 million from Phillip T. (Terry) and Susan M. Ragon, and with an additional $200 million gift to endow the Institute announced on April 26, 2019, the Institute is structured and positioned to significantly contribute to a global effort to successfully develop an HIV/AIDS vaccine by: • Creating non-traditional partnerships among experts with different but complementary backgrounds; • Providing a means for rapidly funding promising studies; • Integrating key facets of vaccine development efforts that have tended to follow separate tracks; • Providing a substantial pool of accessible, flexible funding that lowers the threshold for scientists to pursue risky, unconventional avenues of study that are unlikely to attract funding from traditional sources. Such funding encourages innovation, compresses the time it takes to conduct bench-to-bedside research and attracts new minds to the field. The Ragon Institute creates a singular opportunity and environment to engage scientists, engineers and clinicians in challenging research for which there is no greater benefit – saving lives and curing the ill.